Literature DB >> 1826407

Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis.

M D Tabernero1, J F Tomas, I Alberca, A Orfao, A Lopez Borrasca, V Vicente.   

Abstract

At present, different congenital defects in several proteins--antithrombin III (AT III), protein C (PC), protein S (PS), and plasminogen (PLG)--are known to be causes of hereditary predisposition to thrombosis (thrombophilia). The incidence of these hereditary disorders in our 204 patients (106 males and 98 females) with venous thromboembolism were 4% (three cases deficient in PC, three in PS, two in PLG, and one patient in AT III). Their families were studied. In all cases the disorders were inherited as an autosomal dominant trait. The first thrombotic episodes occurred at a age of below 40 years. There was no relationship between protein levels and the occurrence of thrombosis, although a significant relationship was observed between a positive history of thromboembolic disease and a diagnosis of protein deficiencies. We evaluated the differences between primary thrombosis and secondary thrombosis. The most common thrombotic sites were the deep veins. There were no differences between males and females. Evaluation of PC, PS, AT III, and PLG in patients with thromboembolic disease should be considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826407     DOI: 10.1002/ajh.2830360405

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

Review 3.  Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.

Authors:  U Nowak-Göttl; K Auberger; U Göbel; W Kreuz; R Schneppenheim; H Vielhaber; W Zenz; B Zieger
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

4.  Activated protein C resistance in patients with central retinal vein occlusion.

Authors:  J Larsson; A Sellman; B Bauer
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

Review 5.  Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.

Authors:  B Dahlbäck
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

6.  Activated protein C resistance in young adults with central retinal vein occlusion.

Authors:  J Larsson; E Olafsdottir; B Bauer
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

7.  Deep venous thrombosis following different isolated lower extremity fractures: what is known about prevalences, locations, risk factors and prophylaxis?

Authors:  S Decker; M J Weaver
Journal:  Eur J Trauma Emerg Surg       Date:  2013-02-21       Impact factor: 3.693

8.  Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.

Authors:  A L Jones; T J Powles; J G Treleaven; J F Burman; M C Nicolson; H I Chung; S E Ashley
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.